ARIADNE is composed of two platforms: ARIADNE-Criblage, High-Content and High-throughput-Screening Platform and ARIADNE-ADME.

Working independently but complementary, their objective is to discover small chemical molecules useful in therapy or to explore the living, and to characterize their ADME properties. ARIADNE-Criblage brings together a set of expertise and equipment dedicated to the screening of biological disruptors such as small chemical molecules or siRNA libraries. ARIADNE-ADME allows to quantify the parameters which characterize the ability of molecules to be Absorbed, Distributed, Metabolized and Eliminated in vivo (ADME). Evaluation of ADME parameters early in the discovery process is widely used during target validation, hit-discovery, hit-to-lead optimisation stages